| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | ADARx Pharmaceuticals | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $505M | Series C | 8/9/2023 | $200M | $827.77M | $8.32 | Bain Capital Life Sciences, TCGX, Blackrock, Commodore Capital, Cormorant Asset Management, HBM Healthcare Investments, Invus, Marshall Wace, Redmile Group, T. Rowe Price Associates, Venrock Healthcare Capital Partners, Vivo Capital, Ascenta Capital, Lilly Asia Ventures, OrbiMed Advisors, SR One Capital Management | ||||
 | Cityblock Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | $825.00K | -- | 1 | $15.38 | -0.90% | -15.86% | $1.83B | Series X | 6/18/2024 | $39M | $1.58B | $19.91 | Undisclosed Investors | ||||
 | Pelage | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $150.75M | Series B | 10/15/2025 | $120M | $314.7M | $7.23 | ARCH Venture Partners, GV, Main Street Advisors, Visionary Ventures, YK Bioventures | ||||
 | Resilience | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $4.18B | Series D | 6/6/2022 | $625M | $8.84B | $60.73 | Undisclosed Investors | ||||
 | Calm | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $442.28M | Series 1 | 2/29/2024 | $25.07M | $404.67M | $2.38 | Undisclosed Investors | ||||
 | HeartFlow | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $755.52M | Series F | 4/6/2023 | $174.86M | $546.5M | $2.85 | Bain Capital, Janus Henderson Investors, Baillie Gifford, Capricorn Investment Group, Hayfin Capital Management, HealthCor, Martis Capital, USVP, Wellington Management | ||||
 | Omada Health | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $444.57M | Series E | 2/23/2022 | $197.55M | $1.01B | $17.99 | Fidelity, aMoon, Perceptive Advisors, Wellington Management, Civilization Ventures | ||||
 | Lyra Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $926.79M | Series G | 1/19/2022 | $235M | $5.58B | $18.23 | Dragoneer, Salesforce Ventures, Coatue | ||||
 | Midi Health | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $251.97M | Series D | 2/3/2026 | $100M | $1B | $10.06 | Goodwater Capital, Foresite Capital, Serena Ventures, Advance Venture Partners, GV, Emerson Collective, SemperVirens, McKesson Ventures, Felicis | ||||
 | NewLimit | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $100.13K | -- | 1 | -- | Not available | -- | -- | $682.09M | Series C-2 | 6/2/2026 | $210M | $3.1B | $53.47 | Founders Fund, Thrive Capital, Greenoaks, Quiet Capital, Kleiner Perkins, Abstract, NFDG, Valor Equity Partners, Lilly Ventures, Human Capital | ||||
 | Cellares | Healthcare Healthcare Providers & Services | Low | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $639.25M | Series D-1 | 5/6/2026 | $26.49M | $1.4B | $11.99 | Undisclosed Investors | ||||
 | Chai Discovery | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $500.00K | -- | 1 | -- | Not available | -- | -- | $620.17M | Series C | 7/14/2026 | $400M | $3.8B | $178.05 | Index Ventures, Kleiner Perkins, Sequoia Capital, Dimension, Bain Capital Ventures, Battery Ventures, Baillie Gifford, BDT & MSD, Sapphire Ventures, Avra Capital, Thrive Capital, OpenAI, Oak HC/FT, Menlo Ventures, General Catalyst, Glade Brook, Avenir, Lachy Groom, Yosemite, Scribble Ventures | ||||
 | Mark Cuban Cost Plus Drug Company | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | ROM Technologies | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Sword Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $540.19M | Junior | 1/16/2026 | $175.33M | $4.15B | $71.51 | Undisclosed Investors | ||||
 | Verse Medical | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $109.43M | Series C | 6/10/2025 | $53M | $735.18M | $32.37 | General Catalyst, SignalFire, Sapphire Ventures | ||||
 | Cytonics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Emerald Cloud Lab | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $151.12M | New Series C-1 | 7/25/2025 | $65M | $335.94M | $0.51 | Undisclosed Investors | ||||
 | Headspace | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | $2.7M | -- | 2 | Not available | -- | -- | $74.08M | Series B | 7/3/2017 | $38.65M | $298.33M | $1.93 | Spectrum Equity | ||||
 | Human Longevity | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $91.95M | Series B-1 | 8/21/2024 | $32M | $185.79M | $0.31 | TVM Capital Healthcare, Panacea Venture, Emerging Technology Partners, Shin Ryoku Trust | ||||
 | Zus Health | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Aledade | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | $247.91K | -- | 1 | Not available | -- | -- | $696.82M | Series F | 6/21/2023 | $260M | $3.52B | $50.12 | Lightspeed Venture Partners, Venrock, Avidity Partners, OMERS Growth Equity, Fidelity | ||||
 | Ginkgo Bioworks | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $785.53M | Series E | 5/28/2020 | $360M | $4.89B | $150.19 | T. Rowe Price, Allen & Company, Baillie Gifford, Cascade Investment, General Atlantic, Reshape Holdings, Viking Global Investors, Illumina | ||||
 | Aragen Life Sciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||